Drugs Made In America Acquisition II Corp（DMII）價格預測

$10.155

+0.005 (+0.05%)收盤時

價格預測

1-Day Price Prediction

-0.04%

1-Week Prediction

-2.27%

1-Month Prediction

—

2026 Prediction

—

2030 Prediction

—

在 App 中開啟以解鎖更長週期的預測。

Loading chart…

DMII 相似圖表分析預測

Alphio's DMII stock price prediction model matches the current Drugs Made In America Acquisition II Corp tape against historical breakout patterns, then publishes 1-day and 1-week targets first. The 1-day print is $10.15 (-0.04%). The 1-week path is $9.92 (-2.27%). Longer windows use the same pattern set plus seasonality; the 1-month and multi-year forecasts sit behind unlock because they include precise min / avg / max bands.

該買進 Drugs Made In America Acquisition II Corp 股票嗎？

Currently, DMII is not a strong buy due to its mixed financial performance and lack of significant momentum indicators. The stock is priced at $10.14, with an RSI of 56.83 indicating it is neither overbought nor oversold. However, the forward P/E ratio is 0, suggesting a lack of expected earnings growth, which is a concern for long-term investors.

DMII 股價於 Tuesday 收在 $10.16，此前上漲 +0.05%

Drugs Made In America Acquisition II Corp (DMII) last closed at $10.155, gaining +0.05%. These facts feed the 1-day and 1-week DMII price prediction above.